Experience of Using an App in HIV Patients Older Than 60 Years: Pilot Program (Preprint)

Abstract

Background: The elderly HIV patient population not only presents more comorbidity and poly-medication, but also suffers from stigmatization on behalf of society and lack of social support, where new technologies can now play a role towards enhancing the empowerment of these patients.

Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single‐tablet regimen in a multicentre cohort in Spain

“…To our knowledge, the de-simplification of the STR DTG/ ABC/3TC to DTG+(ABC/3TC)g has only been evaluated by two single-centre studies in pre-treated patients: both found this strategy to be safe and effective [20,21]. Olalla et al found that during the first six months after switching to DTG+(ABC/3TC)g among 93 patients that were receiving DTG/ABC/3TC, no patients had VL above 400 copies/mL (five of the patients had VL between 50 and 400 copies/mL), and only two patients interrupted their treatment due to central nervous system side effects; the adherence measured in the hospital pharmacy was 98% before and after the switch [21]. Krentz et al compared 441 patients who remained on DTG/ ABC/3TC to 257 patients who either initiated or switched to DTG+(ABC/3TC)g and found that 3.6% and 1.2% of patients discontinued therapy and 3.4% and 1.2% of patients had any viral load >500 copies/mL respectively [20].…”

“…However, most of these studies have analysed STRs that are no longer recommended as first-line therapy in high-income countries [16][17][18][19]. To our knowledge, only two single-centre studies have evaluated the de-simplification of the STR dolutegravir/abacavir (ABC)/lamivudine (3TC), with high rates of virological effectiveness in a limited number of patients [20,21], but data on the comparative effectiveness of DTG/ABC/3TC versus its separate components (DTG+ABC/3TC) in treatment-na€ ıve patients are lacking.…”